Quest Diagnostics (DGX)
Health Care · diagnostic laboratories · NYSE
A leading national provider of diagnostic testing and medical insights, delivering clinical laboratory services through an extensive network of patient centers and hospitals.
What Quest Diagnostics does
Quest Diagnostics is a provider of diagnostic testing, information, and services. The company operates a national network of clinical laboratories, patient service centers, and rapid response laboratories, providing medical insights to patients, physicians, hospitals, and employers.
Themes: diagnostic testing, clinical laboratory services, precision medicine, healthcare analytics
Fundamentals
- Price$244.39 as of 2026-08-21 close
- Market cap$27.0B as of 2026-08-21
- 1-year return+33.0% 2025-08-21 close $183.72 → 2026-08-21 close $244.39
- P/E24.62 as of 2026-08-24
- Net margin+9.2% as of 2026-08-24
- Gross margin+33.2% as of 2026-08-24
- ROE+14.5% as of 2026-08-24
- Debt / equity0.75 as of 2026-08-24
- Revenue growth (YoY)+9.9% as of 2026-08-24
- Revenue CAGR (3y)+3.7% SEC XBRL
- Beta0.54 as of 2026-08-24
- Last reported earnings2026-07-23 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +2.1%; at least 5 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How DGX compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 71 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)top 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DGX is in the Health Care Long-term Top 10.
Health Care Long-term Top 10 — since 18 Aug 2026
Long-term score
59.0 #210 of 987 scored · #9 of 57 in Health Care
Long-term trend 90th (it is at or near its highest point of the past year) and capital return 71st (consecutive years of dividend increases 5 years); weakest is profitability (46th, operating margin 14.1%, return on equity 14.5%).
Short-term score
55.7 #440 of 1,704 scored · #84 of 240 in Health Care
Volume and participation 91st: it gapped 8.7% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; trend 87th: a "golden cross" — its 50-day average is above its 200-day; weakest is momentum 39th: near the top of its 14-day range (overbought). Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
In this list since 18 Aug 2026 — currently 9th in the list (3 days)
- Entered 18 Aug 2026: first selection for this list at rank 9, score 56.2.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, DGX's dividend was covered by reported results (earnings payout 36%, free-cash-flow payout 26%). This describes past coverage, not a forecast.
- Earnings payout36% dividends / net income
- Free-cash-flow payout26% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Quest Diagnostics looks technically
Quest Diagnostics (DGX) is trading 23.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 571 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control. Momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70). MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative). It just made a new 20-day high, pushing above its recent trading range. It is 0.5% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 23.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +23.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $219.31 | $219.31 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $197.91 | $197.91 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 24 calendar days ago — the swings before that are what the structure reading is measured on | 24 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 219.2. It is the only labelling that fits, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 571 trading days ago — a "golden cross", a bullish long-term signal | 571 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 37, with buyers in control | 36.8 |
Momentum
3
| 14-day RSI | momentum is stretched — its 14-day RSI (a 0–100 momentum gauge) is 75, in overbought territory (above 70) | 74.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($229.75 to $245.68) — its "stochastic" reading is 92 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 91.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 7 trading days ago (its momentum flipped negative) | 7 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $245.68 | $245.68 |
|---|---|---|
| From the 52-week high | it is 0.5% below its 52-week high (its highest price of the past year) | -0.5% |
| Above the 52-week low | it is 42.8% above its 52-week low (its lowest price of the past year) | +42.8% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.5% |
| Since a 20-day breakout | it just made a new 20-day high, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $245.68 (set on 2026-08-20) | $245.68 |
| Given back of the 52-week move | over the past year its closes ranged ($173.49 to $244.39), and it has given back essentially none of its rise from last year’s low — 0% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $198.31 to $200.57. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.0% |
| From the all-time high | it is 0.5% below its all-time high | -0.5% |
| Nearest price level | it is trading 12.7% above a support level at $213.35 — a price it turned at twice since 2026-02-12, most recently on 2026-02-27. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -12.7% |
| All-time low | its lowest closing price on record is $38.66 (set on 2008-10-17) | $38.66 |
| Above the all-time low | it is 532.2% above its all-time low | +532.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 88% of it) | 12th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.34 between its high and its low — about 2.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.34 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $230.25 and $242.88 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $230.25 – $236.56 – $242.88 |
| Typical daily range (% of price) | its price moves about 2.2% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.2% |
| Stretch from the 200-day average | it is trading 8.7 daily ranges above its 200-day average price (23.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.7 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.35× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Open gap | it gapped 8.7% above the previous close 21 sessions ago and has not traded back through the level it left behind at 209.83 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +8.7% |
| Gap filled | a 2.2% gap down opened on 2026-07-14 has been "filled" 28 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 28 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 15.8 percentage points (the stock gained 18.2% while the market gained 2.3%) | +15.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 23.0 percentage points (the stock gained 26.1% while the market gained 3.1%) | +23.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 9.7 percentage points (the stock gained 20.7% while the market gained 11.1%) | +9.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 12.5 percentage points (the stock gained 33.0% while the market gained 20.5%) | +12.5% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: its RSI momentum gauge is overbought (a stretched reading), MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 17% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 2.2% of the share price. | +17.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 20% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $203.47 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +20.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% above the average price paid since it last reported on 2026-07-23 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $234.74 — a volume-weighted average of daily closes over 22 sessions, not a true tick-by-tick VWAP. | +4.1% |
Price levels it has turned at before
DGX last closed at $244.39 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $213.35 | Support | 12.7% below the last close | turned there twice · 2026-02-12 to 2026-02-27 |
| $206.25 | Support | 15.6% below the last close | turned there twice · 2026-03-13 to 2026-06-11 |
| $201.50 | Support | 17.6% below the last close | turned there four times · 2026-02-20 to 2026-07-14 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $219.20.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $220.58 and $230.85 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Overbought (14-day RSI above 70) · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Near the all-time high | Learn: moving average · golden cross · adx · rsi · macd · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$245.87 range $204.00 – $265.00; median $250.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DGX
- Consensus EPS estimate$2.86 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Changes in government and private payer reimbursement policies for diagnostic services.","Operational risks related to the integration of acquired businesses.","Dependence on continued regulatory compliance and laboratory accreditation standards."]
What changed in the latest 10-Q
AI-assisted comparison of DGX's 10-Q filed 2026-04-22 against the prior one filed 2025-10-21.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing shows Q1 2026 financial data (three months ended March 31, 2026) compared to older filing showing Q3 2025 financial data (three and nine months ended September 30, 2025)
- Newer filing consolidated statements include only three-month comparison (March 31, 2026 vs 2025); older filing includes both three-month and nine-month comparisons
- Newer filing balance sheet dated March 31, 2026 and December 31, 2025; older filing balance sheet dated September 30, 2025 and December 31, 2024
- Newer filing cash flows statement covers three months ended March 31, 2026 and 2025; older filing covers nine months ended September 30, 2025 and 2024
- Newer filing stockholders' equity statement shows only Q1 2026 three-month period; older filing shows both three-month and nine-month periods for 2025
- Business acquisitions line item in newer filing shows $38 million net of cash acquired for Q1 2026 (newer) vs $0 in Q1 2025 (newer)
- MD&A page references changed: Item 2 at page 23 in newer filing vs page 28 in older filing; Item 3 at page 33 in newer vs page 40 in older; Item 4 at page 33 in newer vs page 40 in older
- Removed:
- Older filing consolidated statements of comprehensive income line item 'Net deferred gain on cash flow hedges, net of taxes' ($0 and $3 million for three and nine months) removed in newer filing
- Older filing consolidated statements of operations line item 'Other income, net' ($8 million for Q3 2025, $18 million for nine months) changed to 'Other expense, net' ($2 million in newer Q1 2026 and $3 million in newer Q1 2025)
- Older filing cash flows statement included 'Purchases of treasury stock' ($150 million for nine months 2025) not present in newer three-month statement
- Older filing stockholders' equity statement shows 'Purchases of treasury stock' ($1 million shares and $150 million cost) line item not present in newer filing
- Reworded:
- Consolidated statements of comprehensive income item changed from 'Other comprehensive (loss) income' in older to 'Other comprehensive (loss) income' in newer (same label but different reported amounts reflecting different reporting periods)
- Consolidated statements of operations: 'Other operating expense, net' replaced 'Other operating expense, net' with different amounts ($2 million in Q1 2026 vs $23 million in Q3 2025)
- Cash flows from operating activities: 'Deferred income tax expense' changed to reflect different amounts ($48 million in Q1 2026 vs $118 million for nine months in older filing)
- Notes:
- The two filings report different fiscal periods (Q1 2026 vs Q3 2025), making direct financial metric comparisons reflect both temporal differences and company performance changes
- Statement of comprehensive income structure simplified in newer filing by removing cash flow hedges line item
- Stockholders' equity statement for newer filing appears truncated at bottom of provided text, limiting full comparison of Q1 2025 period details
Risk Factors
- Added:
- Newer filing (2026-04-22) adds Item 1A reference to Annual Report Form 10-K for year ended December 31, 2025 (vs. 2024 in older filing)
- Newer filing adds disclosure that Board of Directors increased share repurchase program by $1 billion in February 2026
- Newer filing adds disclosure that total authorized share repurchases reached $14 billion through March 31, 2026
- Newer filing adds Rule 10b5-1 trading arrangement for Karthik Kuppusamy, SVP Clinical Solutions, adopted February 26, 2026, covering up to 8,147 shares
- Newer filing adds Exhibit 10.1 Form of Quest Diagnostics Incorporated 2026 Equity Award Agreement
- Removed:
- Older filing (2025-10-21) references Annual Report Form 10-K for year ended December 31, 2024; removed in newer filing
- Older filing discloses share repurchase activity for Q3 2025 (July-September); removed in newer filing
- Older filing reports $735,920 thousand approximate dollar value remaining under repurchase program as of September 30, 2025; removed in newer filing
- Older filing discloses Rule 10b5-1 trading arrangement for Jim Davis (Chairman, CEO, and President) adopted August 26, 2025; removed in newer filing
- Older filing discloses Rule 10b5-1 trading arrangement for Mark Delaney (SVP and Chief Commercial Officer) adopted August 18, 2025; removed in newer filing
- Reworded:
- Risk Factors Item 1A statement updated from 'December 31, 2024' to 'December 31, 2025'
- Item 2 heading changed from 'third quarter of 2025' to 'first quarter of 2026'
- Share repurchase program footnote (A) in newer filing adds statement 'In February 2026, our Board of Directors increased the size of our share repurchase program by $1 billion' and updates total authorized from '$13 billion' to '$14 billion'
- Notes:
- The two filings report different fiscal periods (Q3 2025 vs. Q1 2026) and different year-end dates (September 30, 2025 vs. March 31, 2026), which accounts for differences in reported share repurchase activity and officer trading arrangements
- This comparison focuses on Risk Factors section and related Item 2, Item 5, and Item 6 disclosures as provided
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($376288) — 1 selling insider
- Last 90 days0 buys · 3 sells ($4M) — 3 selling insiders
- Last 180 days0 buys · 3 sells ($4M) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-28. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DGX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 5 matched disclosures for DGX from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding DGX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 15,988,320
- Reported value $3,133,390,969
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 0 increased, 5 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DGX had 3,684,192 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
DGX had 3.34% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.74 days to cover at the same settlement.
- Reported short interest (shares) 3,684,192
- Short interest (% of shares outstanding) 3.34%
- Prior settlement (shares) 3,509,407
- Reported change 4.98%
- Days to cover (reported) 2.74
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Laboratory Corporation of America (LH)
- Eurofins Scientific (ERFSF)
- Sonic Healthcare (SKHCF)
- OPKO Health (OPK)
- Exact Sciences (EXAS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DGX vs…
Quest Diagnostics is found in…
Frequently asked questions
What does Quest Diagnostics (DGX) do?
Quest Diagnostics is a provider of diagnostic testing, information, and services. The company operates a national network of clinical laboratories, patient service centers, and rapid response laboratories, providing medical insights to patients, physicians, hospitals, and employers.
What sector is Quest Diagnostics (DGX) in?
Quest Diagnostics (DGX) is classified in the Health Care sector. Its industry is diagnostic laboratories. It trades on NYSE.
Does DGX pay a dividend?
Yes — Quest Diagnostics (DGX) pays a dividend, with an indicated yield of about 2.10% and at least 5 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-08-24). Informational only — not financial advice.
Who are Quest Diagnostics's (DGX) competitors?
Notable peers of Quest Diagnostics (DGX) include Laboratory Corporation of America, Eurofins Scientific, Sonic Healthcare, OPKO Health and Exact Sciences. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in DGX?
Yes — we hold 5 matched STOCK Act disclosures for DGX from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Quest Diagnostics (DGX) overbought or oversold right now?
Quest Diagnostics (DGX) is currently in overbought territory (its 14-day RSI is 75, above 70) (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DGX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.